Neurotensin is an antagonist of the human neurotensin NT2 receptor expressed in Chinese hamster ovary cells

被引:124
作者
Vita, N
Oury-Donat, F
Chalon, P
Guillemot, M
Kaghad, M
Bachy, A
Thurneyssen, O
Garcia, S
Poinot-Chazel, C
Casellas, P
Keane, P
Le Fur, G
Maffrand, JP
Soubrie, P
Caput, D
Ferrara, P
机构
[1] Sanofi Rech, F-31676 Labege, France
[2] Sanofi Rech, F-34184 Montpellier, France
[3] Sanofi Rech, F-31036 Toulouse, France
关键词
neurotensin; G-protein; receptor; levocabastine; SR142948A; SR48692;
D O I
10.1016/S0014-2999(98)00678-5
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
The human levocabastine-sensitive neurotensin NT2 receptor was cloned from a cortex cDNA Library and stably expressed in Chinese hamster ovary (CHO) cells in order to study its binding and signalling characteristics. The receptor binds neurotensin as well as several other ligands already described for neurotensin NT1 receptor. It also binds levocabastine, a histamine H-1 receptor antagonist that is not recognised by neurotensin NT1 receptor. Neurotensin binding to recombinant neurotensin NT2 receptor expressed in CHO cells does not elicit a biological response as determined by second messenger measurements. Levocabastine, and the peptides neuromedin N and xenin were also ineffective on neurotensin NT2 receptor activation. Experiments with the neurotensin NT1 receptor antagonists SR48692 and SR142948A, resulted in the unanticipated discovery that both molecules are potent agonists on neurotensin NT2 receptor. Both compounds, following binding to neurotensin NT2 receptor, enhance inositol phosphates (IP) formation with a subsequent [Ca2+](i) mobilisation; induce arachidonic acid release; and stimulate mitogen-activated protein kinase (MAPK) activity. Interestingly, these activities are antagonised by neurotensin and levocabastine in a concentration-dependent manner. These activities suggest that the human neurotensin NT2 receptor may be of physiological importance and that a natural agonist for the receptor may exist. (C) 1998 Elsevier Science B.V. All rights reserved.
引用
收藏
页码:265 / 272
页数:8
相关论文
共 26 条
[1]   ACTIVATION OF PHOSPHATIDYLINOSITOL TURNOVER BY NEUROTENSIN RECEPTORS IN THE HUMAN COLONIC ADENOCARCINOMA CELL-LINE HT29 [J].
AMAR, S ;
KITABGI, P ;
VINCENT, JP .
FEBS LETTERS, 1986, 201 (01) :31-36
[3]   Effects of SR 48692 on neurotensin-induced calcium-activated chloride currents in the Xenopus oocyte expression system: Agonist-like activity on the levocabastine-sensitive neurotensin receptor and absence of antagonist effect on the levocabastine insensitive neurotensin receptor [J].
Botto, JM ;
Guillemare, E ;
Vincent, JP ;
Mazella, J .
NEUROSCIENCE LETTERS, 1997, 223 (03) :193-196
[4]   Stable expression of the mouse levocabastine-sensitive neurotensin receptor in HEK 293 cell line: Binding properties, photoaffinity labeling, and internalization mechanism [J].
Botto, JM ;
Chabry, J ;
Sarret, P ;
Vincent, JP ;
Mazella, J .
BIOCHEMICAL AND BIOPHYSICAL RESEARCH COMMUNICATIONS, 1998, 243 (02) :585-590
[5]  
CARRAWAY R, 1973, J BIOL CHEM, V248, P6854
[6]   DISTRIBUTION AND IMMUNOCHEMICAL CHARACTER OF NEUROTENSIN-LIKE MATERIAL IN REPRESENTATIVE VERTEBRATES AND INVERTEBRATES - APPARENT CONSERVATION OF THE COOH-TERMINAL REGION DURING EVOLUTION [J].
CARRAWAY, R ;
RUANE, SE ;
KIM, HR .
PEPTIDES, 1982, 3 (02) :115-123
[7]   Molecular cloning of a levocabastine-sensitive neurotensin binding site [J].
Chalon, P ;
Vita, N ;
Kaghad, M ;
Guillemot, M ;
Bonnin, J ;
Delpech, B ;
LeFur, G ;
Ferrara, P ;
Caput, D .
FEBS LETTERS, 1996, 386 (2-3) :91-94
[8]  
CHOMCZYNSKI P, 1987, ANAL BIOCHEM, V162, P156, DOI 10.1016/0003-2697(87)90021-2
[9]   Cloning and characterization of human urocortin [J].
Donaldson, CJ ;
Sutton, SW ;
Perrin, MH ;
Corrigan, AZ ;
Lewis, KA ;
Rivier, JE ;
Vaughan, JM ;
Vale, WW .
ENDOCRINOLOGY, 1996, 137 (05) :2167-2170
[10]   THE NONPEPTIDE NEUROTENSIN ANTAGONIST, SR-48692 USED AS A TOOL TO REVEAL PUTATIVE NEUROTENSIN RECEPTOR SUBTYPES [J].
DUBUC, I ;
COSTENTIN, J ;
TERRANOVA, JP ;
BARNOUIN, MC ;
SOUBRIE, P ;
LEFUR, G ;
ROSTENE, W ;
KITABGI, P .
BRITISH JOURNAL OF PHARMACOLOGY, 1994, 112 (02) :352-354